Literature DB >> 27659831

Clinical considerations and surgical approaches for low-grade gliomas in deep hemispheric locations: thalamic lesions.

Tai-Tong Wong1,2, Hsin-Hung Chen3, Muh-Lii Liang3, Kevin Li-Chun Hsieh4,5, Yi-Shan Yang3, Donald Ming-Tak Ho6, Kai-Ping Chang7, Yi-Yen Lee3, Shih-Chieh Lin6, Ting-Rong Hsu7, Yi-Wei Chen8, Sang-Hue Yen8, Feng-Chi Chang9, Wan-You Guo9, Kuo-Wei Chen10, Wei-Kang Kwang11, Wu-Yu Hou12, Chung-Yih Wang13.   

Abstract

BACKGROUND: Tumors with epicenter in the thalamus occur in about 4 % of pediatric brain tumors. The histological diagnosis is mainly gliomas. Among them, low-grade glioma (LGG) constituted of a significant entity of the tumors (Cuccia et al., Childs Nerv Syst 13:514-521, 1997; Puget et al., J Neurosurg 106:354-362, 2007; Bernstein et al., J Neurosurg 61:649-656, 1984; Bilginer et al., Childs Nerv Syst 30:1493-1498, 2014). Since Kelly's report in 1989, >90 % resection of thalamic tumors were achieved in reported series (Ozek and Ture, Childs Nerv Syst 18:450-6, 2002; Villarejo et al., Childs Nerv Syst 10:111-114, 1994; Moshel et al., Neurosurgery 61:66-75, 2007; Albright, J Neurosurg 100(5 Suppl Pediatrics): 468-472, 2004; Kelly, Neurosurgery 25:185-195, 1989; Drake et al., Neurosurgery 29: 27-33, 1991).
MATERIALS AND METHODS: Sixty-nine cases of thalamic tumors in children were retrospectively reviewed. There were 25 cases of LGGs. We analyzed our experience and correlated it with reported series.
RESULTS: Summing up of 4 reported series and the present series, there were 267 cases of thalamic tumors in children. Among these tumors, 107 (40.1 %) were LGGs and 91 (34.1 %) were low-grade astrocytomas (LGAs). In the present series, all of the 25 LGGs were LGAs that consisted of 11 pilocytic astrocytomas (PAs) and 14 diffuse astrocytomas (DAs). Six cases received biopsy sampling only. The remaining 19 cases received different degrees of surgical resection via several approaches. Radical (>90 %) resection was achieved better in PAs comparing with DAs. There was no operative mortality. Two patients had increased neurological deficits. In a mean follow-up period of 11.9 years, three patients died of tumor progression and one patient died of anaplastic change. The 5- and 10-year overall survival (OS) was 87.1 and 87.1 %, respectively.
CONCLUSION: Thalamic LGGs are mainly LGAs and are indolent. The rate of >90 % resection was relatively low in the present series. By applying contemporary diagnostic MRI studies, surgical facilities, and appropriate approaches in selective cases, we may try maximum neuroprotective radical (>90 %) resection.

Entities:  

Keywords:  Children; Low-grade glioma; Outcome; Surgical approach; Thalamic tumor

Mesh:

Year:  2016        PMID: 27659831     DOI: 10.1007/s00381-016-3148-5

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  29 in total

1.  Thalamic tumors in children.

Authors:  Burcak Bilginer; Firat Narin; Ilkay Işıkay; Kader Karlı Oguz; Figen Söylemezoglu; Nejat Akalan
Journal:  Childs Nerv Syst       Date:  2014-04-22       Impact factor: 1.475

Review 2.  Hydrocephalus with brain tumors in children.

Authors:  Tai-Tong Wong; Muh-Lii Liang; Hsin-Hung Chen; Feng-Chi Chang
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

3.  Thalamic tumors in children.

Authors:  V Cuccia; J Monges
Journal:  Childs Nerv Syst       Date:  1997-10       Impact factor: 1.475

4.  Involution of diencephalic pilocytic astrocytoma after partial resection. Report of two cases in adults.

Authors:  K B Balkhoyor; M Bernstein
Journal:  J Neurosurg       Date:  2000-09       Impact factor: 5.115

5.  Stereotactic biopsy and resection of thalamic astrocytomas.

Authors:  P J Kelly
Journal:  Neurosurgery       Date:  1989-08       Impact factor: 4.654

6.  Radical surgery of thalamic tumors in children.

Authors:  F Villarejo; C Amaya; C Pérez Díaz; A Pascual; C Alvarez Sastre; F Goyenechea
Journal:  Childs Nerv Syst       Date:  1994-03       Impact factor: 1.475

7.  Feasibility and advisability of resections of thalamic tumors in pediatric patients.

Authors:  A Leland Albright
Journal:  J Neurosurg       Date:  2004-05       Impact factor: 5.115

8.  Thalamic tumors in children: a reappraisal.

Authors:  Stephanie Puget; Darach W Crimmins; Matthew R Garnett; Jacques Grill; Ricardo Oliveira; Nathalie Boddaert; Alison Wray; Arielle Lelouch-Tubiana; Thomas Roujeau; Federico Di Rocco; Michel Zerah; Christian Sainte-Rose
Journal:  J Neurosurg       Date:  2007-05       Impact factor: 5.115

9.  Neuroimaging of thalamic tumors in children.

Authors:  Cesare Colosimo; Giuseppe Maria di Lella; Tommaso Tartaglione; Riccardo Riccardi
Journal:  Childs Nerv Syst       Date:  2002-07-30       Impact factor: 1.475

10.  Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database.

Authors:  Pratiti Bandopadhayay; Guillaume Bergthold; Wendy B London; Liliana C Goumnerova; Andres Morales La Madrid; Karen J Marcus; Dongjing Guo; Nicole J Ullrich; Nathan J Robison; Susan N Chi; Rameen Beroukhim; Mark W Kieran; Peter E Manley
Journal:  Pediatr Blood Cancer       Date:  2014-01-30       Impact factor: 3.167

View more
  3 in total

Review 1.  Thalamic tumors in children: case series from our institution and literature review.

Authors:  Daniela Renedo; Florencia Ferraro; Agustín Ruiz Johnson; Romina Argañaraz; Sebastian Giovannini; Joaquín Pérez Zabala; Elena Zemma; Beatriz Mantese
Journal:  Childs Nerv Syst       Date:  2020-07-25       Impact factor: 1.475

2.  Distant recurrences limit the survival of patients with thalamic high-grade gliomas after successful resection.

Authors:  Ryuta Saito; Toshihiro Kumabe; Masayuki Kanamori; Yukihiko Sonoda; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2016-12-17       Impact factor: 3.042

Review 3.  Pediatric Glioma at the Optic Pathway and Thalamus.

Authors:  Eun Suk Park; Jun Bum Park; Young-Shin Ra
Journal:  J Korean Neurosurg Soc       Date:  2018-05-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.